Application note: Pharmaceutical analysis using UV-Vis: compliance with USP Chapter <857> and European pharmacopoeia (Ph. Eur. Chapter 2.2.25)
Posted: 25 June 2020 | Agilent Technologies | No comments yet
USP general chapter <857> and Ph. Eur. chapter 2.2.25 guide instrument operational qualification protocols for UV-Vis spectroscopy. This technical note demonstrates how to ensure qualification as per global pharmacopoeias’ requirements.
UV-Vis spectroscopy is a widely used analytical technique in quality assurance/ quality control (QA/QC) and pharmaceutical research. It is critical that any laboratory in such environments set up appropriate controls for laboratory access and ensure that good manufacturing practice (GMP) documentation, including system suitability tests (SSTs) and standard operating procedures (SOPs) are available and followed. The United States pharmacopoeia (USP) and the European pharmacopoeia (Ph. Eur.) guidelines describe how to verify that the analytical performance of UV-Vis spectrophotometers is suitable for the intended operational range of the analysis.
Related content from this organisation
- Raman spectroscopy market expected to value $875m by 2028
- HPLC market projected to value $8 million by 2030
- ebook: Nanoparticle formulations: overcoming dissolution challenges
- Application note: Rapid identification of Polysorbates 20 and 80 through amber bottles
- Biopharmaceutical bioseparation systems market to value $20bn
Issue
Related topics
Analytical techniques, Good Manufacturing Practice (GMP), QA/QC